Tim Opler

Graig Suvannavejh × Tim Opler × Yaron Werber × Paul Matteis × Brian Skorney

Biotech is decisively outperforming, with XBI +24% YTD versus +9% for the S&P 500, as Graig sees FDA headwinds turning into tailwinds alongside 14 IPOs and $300B+ of pharma revenue at LOE risk.Reverse mergers now rival traditional IPOs, while J&J’s $785M Sail deal and $2.6B acquisition option reinforce hot in vivo CAR-T M&A.Alnylam’s roughly 30% TTR sell-off and Novo’s ZEUS miss leave upcoming data and year-end M&A as key tests.

Chris Garabedian × Daphne Zohar × Sam Fazeli × Tess Cameron × Paul Matteis × Tim Opler

XBI remains down YTD, but this year's IPO cohort is up 50–60% and follow-ons work, signaling a fund-specific recovery amid scarce private capital.China biotech rose almost 40% last month on rumored "$500 million plus" deals, while copycat competition discounts exposed US smid-caps; FDA subjectivity remains a tail risk as KalVista's approval is "very likely" despite an inferential CRL report.

Chris Garabedian × Tim Opler × Bruce Booth × Sam Fazeli

Biotech’s 2025 selloff appears driven more by forced selling and weak marginal demand than deteriorating science, with XBI at $84.45, down 4% for the week.Venture capital remains near $5 billion quarterly while new financings have fallen to barely above 50 and average rounds reached $65 million, concentrating capital in fewer, more disciplined companies.Reported HHS reductions create FDA execution risk as China expands, while Tagrisso’s EGFR-lung-cancer defense keeps physician adoption—not headline efficacy—the key catalyst.

Daphne Zohar × Paul Matteis × Brian Skorney × Tim Opler × Abe Ceesay

Biotech sentiment improved after JPM, but the XBI’s 12% lag versus the S&P kept the shift “less negative,” not risk-on.Stronger 2025 pharma M&A capacity, wall-crossed PIPEs, and GH Research’s 15-to-16-point MADRS difference offered catalysts while exposing access and disclosure tensions.Symbravo’s launch, Ingrezza’s Part D pressure, and Eylea biosimilar erosion leave reimbursement, competition, and execution as key variables.

Chris Garabedian × Tim Opler × Sam Fazeli × Brian Skorney × Luba Greenwood

Novo Nordisk’s Amycretin delivered 22% weight loss at 36 weeks among patients reaching 20 mg and remaining on treatment, but undisclosed discontinuations and limited tolerability data make the as-treated result provisional, making those disclosures the key valuation catalyst.Meanwhile, a roughly 5% technical XBI rebound contrasted with Stifel’s “historic high” M&A pipeline and 17 deals above $75 million upfront in 2024, while health-agency freezes threaten timelines.